PARP Inhibition and its
Evolving Use in the Treatment
A continuing medical education activity sponsored by NAMCP and AAMCN
Inhibition and its Evolving Use in the Treatment of Cancers: What
Managed Care Needs to Know for Improved Clinical and Economic
Outcomes is a 3-part webcast series that will provide
clicking on each of the titles, you will be able to participate in
session has its own specific valid dates
This series is supported by an educational grant from AstraZeneca
Audience: This activity is intended for healthcare professionals practicing in managed care environments.
Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.
To print or save your certificate, you will need to click on the “download” button and either print or save.
These presentations require Adobe Flash Player. You can download it here.
A new class of targeted agents known as poly (ADP-ribose) polymerase (PARP) inhibitors have shown improved efficacy and are leading the way in the treatment of breast, ovarian and prostate cancers. In addition, new indications for these targeted agents offer expanded options in the maintenance setting in varying lines of therapy. This enzyme, known as PARP, is a critical component of DNA base excision repair, essential for the repair of single-strand breaks in DNA. If the action of PARP is inhibited in a normal cell, these breaks are converted to double-strand breaks and repaired through the process of homologous recombination. However, in cells with pre-existing defects in the homologous recombination DNA repair pathway, such as in cancer cells harboring BRCA1/2 mutations, inhibition of PARP results in synthetic lethality. Exploitation of this deficiency with PARP inhibitors create a therapeutic opportunity for tumor cell-specific cell killing. Challenges associated with maximizing therapeutic outcomes with potential PARP inhibitor use in several cancers include selection of optimal testing strategies to personalize care, management of treatment toxicities, and development of evidence-based sequencing and combination strategies.
This multi-part program will provide medical directors, practicing physicians and nurses with the latest clinical data on novel treatments that have recently completed late stage clinical trials. Attendees will be updated on these treatment options and the potential integration of newer agents, in order to optimize the care of their patients.
1. Compare and contrast the safety and efficacy profiles of PARP inhibitors in cancer therapy in ovarian, breast and prostate cancer
2. Assess the managed care considerations of current and emerging PARP inhibitors by exploring where these agents fit into the current cancer management paradigm
3. Apply methods to enable optimal cost management of PARP inhibitors in ovarian, breast and prostate cancer to be realized by multiple oncology stakeholders including managed care organizations
4. Analyze what managed care professionals need to know about PARP inhibitors in cancer care
2. Explore the role of PARP inhibitors in the current oncology treatment landscape including ovarian, breast and prostate cancer
3. Compare PARP inhibitors in cancer therapy including mechanisms of action, delivery methods, dosing and scheduling, efficacy, safety, interactions, and ease of use
4. Analyze the role of genetic testing and biomarkers for the identification of patients with various cancers to be treated with PARP inhibition, including those with BRCA-mutated disease
1. Compare PARP inhibitors in cancer therapy including mechanisms of action, delivery methods, dosing and scheduling, efficacy, safety, interactions, and ease of use
2. Identify strategies for anticipating, recognizing, and managing adverse events of PARP inhibitor therapy in patients with ovarian, breast or prostate cancer
3. Discuss methods to communicate effectively with cancer patients and the multidisciplinary team to understand and address the needs of each patient around PARP inhibitors and improve treatment adherence, quality of life, and survival outcomes
4. Review how treatment strategies can be affected by adverse events based on patient’s individualized needs